CTI BioPharma (CTIC) Reports Q4 Loss of $0.23

March 2, 2017 4:02 PM

CTI BioPharma (NASDAQ: CTIC) reported Q4 EPS of ($0.23), versus ($1.27) reported last year. Revenue for the quarter came in at $9.1 million, versus $11.3 million reported last year.

For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.

Categories

Earnings Guidance